Browsing Tag
GlaxoSmithKline plc
5 posts
GSK bets on activin signalling with $950m 35Pharma acquisition
Discover why GSK plc is acquiring 35Pharma Inc. for $950 million and what HS235 could mean for the future of pulmonary hypertension treatment.
GSK offloads Human Genome Sciences: what’s next for Samsung Biologics’ global ambitions?
Samsung Biologics acquires Human Genome Sciences from GSK for $280M, gaining its first U.S. biologics plant. Find out what this move means for global CDMO strategy.
Can GSK’s Exdensur transform asthma biologics with just two doses per year?
GSK’s Exdensur is now FDA approved as the first biannual biologic for severe asthma. Explore what this means for rivals, payers, and global strategy.
Is GSK stock gearing up for a breakout? Q3 2025 results beat, guidance raised, CEO exits on a high
GSK upgrades 2025 guidance after strong Q3 results, driving a 6.57% stock surge. Find out how Specialty Medicines and Oncology powered this breakout.
UK lands £150bn deal with US giants—what it means for jobs, AI, and clean energy future
UK secures £150bn US investment during State Visit, creating 7,600 jobs in clean energy, AI, and life sciences. Discover which companies are leading.